SARCOMA

Latest News

Elraglusib Gains FDA Rare Pediatric Disease Designation in Ewing Sarcoma
Elraglusib Gains FDA Rare Pediatric Disease Designation in Ewing Sarcoma

November 12th 2024

Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with Ewing sarcoma.

Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment

October 29th 2024

FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma
FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma

September 12th 2024

FDA Grants Priority Review to Vimseltinib Application in Tenosynovial Giant Cell Tumor
FDA Grants Priority Review to Vimseltinib Application in Tenosynovial Giant Cell Tumor

August 16th 2024

Phase 1/2 Trial of Silmitasertib in Sarcoma and Brain Tumors to Proceed
Phase 1/2 Trial of Silmitasertib in Sarcoma and Brain Tumors to Proceed

August 8th 2024

Video Series
Video Interviews
Podcasts

More News